Skip to content

Study · Randomized controlled trial · n = 8 · 2007

6 results

The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.

Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA

Pediatric research1 Dec 2007Cited by 27 (Europe PMC)

PMID17957149 (opens in a new tab)DOI10.1203/pdr.0b013e318159af8c (opens in a new tab)PepBankPUB-17957149
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adolescents with type 1 diabetes, insulin concentrations were similar with pramlintide injection and infusion.

    In plain wordsIn adolescents with diabetes, insulin levels were similar with pramlintide injection and infusion.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeInsulin concentrations
    Study

    n = 8

    Comparator
    Pramlintide infusion
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg/unit of insulin · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Insulin concentrations (p < 0.99) between pramlintide injection versus infusion were similar;
    1 context sentence
    Summary · context
    We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, th…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adolescents with type 1 diabetes, glucose concentrations differed between pramlintide injection and infusion.

    In plain wordsIn adolescents with diabetes, blood glucose differed between pramlintide injection and infusion.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Direction not reportedGlucose concentrations
    Study

    n = 8

    Comparator
    Pramlintide infusion
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg/unit of insulin · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Insulin concentrations (p < 0.99) between pramlintide injection versus infusion were similar; however, glucose concentrations were different (p < 0.0001), with the absence of hypoglycemia during pramlintide infusion [AUC (0-120 min) -0.07 +/- 0.2 versus 1.05 +/- 0.24 mg * h/dL (p < 0.0088)].
    1 context sentence
    Summary · context
    We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, th…
  3. 03HumanRandomized controlled trialSafety outcome

    In adolescents with type 1 diabetes, hypoglycemia was absent during pramlintide infusion.

    In plain wordsIn adolescents with diabetes, no hypoglycemia occurred during pramlintide infusion.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableHypoglycemia during infusion
    Study

    n = 8

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    5 microg/unit of insulin · subcutaneousAs given in this study (human).

    Measurements

    Glucose AUC (0-120 min)
    −0.07 mg * h/dL
    first value of reported pair; group order not stated
    Glucose AUC (0-120 min)
    1.05 mg * h/dL
    second value of reported pair; group order not stated

    Source sentences

    Summary
    Insulin concentrations (p < 0.99) between pramlintide injection versus infusion were similar; however, glucose concentrations were different (p < 0.0001), with the absence of hypoglycemia during pramlintide infusion [AUC (0-120 min) -0.07 +/- 0.2 versus 1.05 +/- 0.24 mg * h/dL (p < 0.0088)].
    1 context sentence
    Summary · context
    We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, th…
  4. 04HumanRandomized controlled trialSafety outcome

    In adolescents with type 1 diabetes, two subjects experienced hypoglycemia with pramlintide injection.

    In plain wordsIn adolescents with diabetes, two subjects had low blood sugar with pramlintide injection.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableHypoglycemia with injection
    Study

    n = 8

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    5 microg/unit of insulin · subcutaneousAs given in this study (human).

    Measurements

    Subjects with hypoglycemia
    2 subjects
    pramlintide injection

    Source sentences

    Summary
    Two subjects experienced hypoglycemia with pramlintide injection.
    1 context sentence
    Summary · context
    We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, th…
  5. 05HumanRandomized controlled trialMechanism

    In adolescents with type 1 diabetes, pramlintide bolus suppressed glucagon more than infusion.

    In plain wordsIn adolescents with diabetes, pramlintide bolus suppressed glucagon more than infusion.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGlucagon suppression
    Study

    n = 8

    Comparator
    Pramlintide infusion
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    5 microg/unit of insulin · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pramlintide bolus caused pronounced glucagon suppression (p < 0.0003) and delayed gastric emptying as ([13CO2] p < 0.0003 and acetaminophen p < 0.01) compared with infusion.
    1 context sentence
    Summary · context
    We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, th…
  6. 06HumanRandomized controlled trialMechanism

    In adolescents with type 1 diabetes, pramlintide bolus delayed gastric emptying compared with infusion.

    In plain wordsIn adolescents with diabetes, pramlintide bolus slowed stomach emptying compared with infusion.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGastric emptying
    Study

    n = 8

    Comparator
    Pramlintide infusion
    Outcome group
    Appetite and food intake · Gastrointestinal
    Studied dose
    5 microg/unit of insulin · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pramlintide bolus caused pronounced glucagon suppression (p < 0.0003) and delayed gastric emptying as ([13CO2] p < 0.0003 and acetaminophen p < 0.01) compared with infusion.
    1 context sentence
    Summary · context
    We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, th…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.